MANKIND

Mankind Pharma, a large-cap player in the Pharmaceuticals and Drugs industry, primarily due to a shift in its technical grade from mildly bearish to bearish. The company's stock price currently stands at 2,344.00, down from a previous close of 2,407.00. Over the past year, Mankind Pharma has experienced a return of -0.65%, while its profits have increased by 49%. However, the company reported a significant decline in its financial performance for Q3 FY24-25, with a profit after tax of Rs 380.23 crore, reflecting a drop of 28.1%. Technical indicators such as MACD and Bollinger Bands are currently bearish, and the stock is trading at a price-to-book value of 9.2, indicating a high valuation relative to its return on equity of 20. Despite these challenges, Mankind Pharma maintains a low debt-to-equity ratio and has seen an increase in institutional holdings by 2.1% in the last quarter.